Search results
Results from the WOW.Com Content Network
The particular PEGylated molecule in the Moderna vaccine is known as DMG-PEG 2000. Pegvaliase (Biomarin) – PEGylated recombinant phenylalanine ammonia-lyase for the treatment of Phenylketonuria, approved by the FDA for the US in May 2018. [22] [23] Adynovate – PEGylated Antihemophilic Factor VIII for the treatment of patients with hemophilia A.
Pegylated interferon alfa-2b is a drug used to treat melanoma, as an adjuvant therapy to surgery. [3] Also used to treat hepatitis C (typically, in combination with ribavarin ), it is no longer recommended due to poor efficacy and adverse side-effects. [ 4 ]
Pegylated interferon alfa-2a, sold under the brand name Pegasys among others, is medication used to treat hepatitis C and hepatitis B. [3] For hepatitis C it is typically used together with ribavirin and cure rates are between 24 and 92%. [3] [4] For hepatitis B it may be used alone. [5] It is given by injection under the skin. [3] Side effects ...
The approval of pegylated E. coli ASNase and ASNase Erwinia chrysantemi has expanded the therapeutic options available for acute lymphoblastic leukemia patients. Ongoing research and clinical trials continue to advance our knowledge and improve outcomes in the treatment of this challenging disease.
In 2013, a phase 3 double blind randomized placebo-controlled study found significantly positive results in patient self-reported questionnaires, with rapid improvement of function and pain reduction, in patients with axial spondyloarthritis. [16] Rheumatoid arthritis Certolizumab appears beneficial in those with rheumatoid arthritis. [17]
Prescient Therapeutics Ltd (Prescient) was created in 2014 by bringing together two small molecule drug assets from separate US private companies (Pathway Oncology for PTX-100 and AKTivate Therapeutics for PTX-200) into the existing ASX-listed shell company Virax Holdings Ltd (Virax).
The company was launched with an initial investment of $120 million, with a remit to develop a pipeline of cancer immunotherapy drugs. [1] The company raised $300 million through private funding and a further $265 million through their IPO. On January 22, 2018, Juno Therapeutics was acquired by biotechnology company Celgene for $9 billion. [2]
Pegloticase is a PEGylated recombinant porcine-like uricase.Similarly to rasburicase, it metabolises uric acid to allantoin.This reduces the risk of urate precipitates, since allantoin is five to ten times more soluble than uric acid.